Skip to main content

Table 2 PTA, SRT, WDS, ART, TOAE, and ABR of the right ear before and after treatment

From: Assessment of auditory function in hepatitis “C” patients managed by combination of sofosbuvir and daclatsavir

Item

Frequency

Pre

Post

T test

P value

PTA

250 Hz

11.30 ± 2.25

11.17 ± 3.11

0.22

0.83

500 Hz

14.00 ± 2.75

13.33 ± 3.56

1.07

0.29

1 kHz

17.50 ± 4.10

16.67 ± 5.47

1.22

0.23

2 kHz

15.50 ± 4.42

17.33 ± 4.69

2.26

0.03*

4 kHz

15.83 ± 3.96

17.50 ± 6.66

1.26

0.03*

8 kHz

15.67 ± 4.10

18.50 ± 8.53

2.38

0.02*

SRT

 

15.00 ± 3.71

15.33 ± 3.93

0.70

0.49

WDS

 

98.13 ± 2.03%

97.40 ± 2.23%

1.44

0.16

ART

500 Hz

86.33 ± 6.42

86.83 ± 5.80

1.14

0.26

1 kHz

87.67 ± 7.16

87.67 ± 6.80

0.00

1.00

2 kHz

89.67 ± 7.98

89.67 ± 7.76

0.00

1.00

4 kHz

89.83 ± 7.13

92.00 ± 8.67

2.36

0.03*

TOAE

0.75–1.25 kHz

10.29 ± 4.05

12.06 ± 6.12

1.62

0.12

1.25–1.75 kHz

14.64 ± 6.53

15.78 ± 6.69

1.09

0.28

1.75–2.50 kHz

13.96 ± 6.48

12.95 ± 9.10

1.01

0.32

2.50–3.50 kHz

12.53 ± 6.74

10.25 ± 7.06

1.60

0.12

3.50–4.50 kHz

8.40 ± 4.31

7.92 ± 3.50

0.47

0.64

Overall

11.21 ± 4.75

11.23 ± 5.57

0.02

0.99

TOAE reproducibility (%)

0.75–1.25 kHz

80.07 ± 14.30

76.63 ± 24.15

0.92

0.37

1.25–1.75 kHz

85.83 ± 18.59

90.37 ± 11.07

1.70

0.10

1.75–2.50 kHz

87.03 ± 13.73

70.30 ± 2.85

3.66

 < 0.001**

2.50–3.50 kHz

81.03 ± 15.78

68.00 ± 5.86

2.75

0.01*

3.50–4.50 kHz

72.40 ± 14.70

61.13 ± 5.63

1.75

0.03*

Overall

79.60 ± 17.72

77.40 ± 19.70

0.81

0.42

ABR, LRR

Wave I

1.71 ± 0.20

1.71 ± 0.23

0.14

0.89

Wave III

3.90 ± 0.18

3.97 ± 0.21

3.21

0.90

Wave V

5.71 ± 0.18

5.93 ± 0.26

3.72

0.87

Inter peak I–III

2.19 ± 0.24

2.26 ± 0.29

1.82

0.76

Inter peak III–V

2.21 ± 0.04

1.96 ± 0.32

0.63

0.53

Inter peak I–V

4.01 ± 0.23

4.22 ± 0.32

3.74

0.84

ABR (HRR)

Wave V

5.99 ± 0.31

6.13 ± 0.44

1.88

0.07

  1. There were statistically significant differences between the two measures regarding PTA, AR, and TEOAE